Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A3 | O15427 | 5/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.80 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.80 |
| ▸ | SLC16A1 | P53985 | 2/20 | 0.80 |
| ▸ | HPGD | P15428 | 2/20 | 0.80 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.80 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.80 |
| ▸ | MAOB | P27338 | 3/20 | 0.68 |
| ▸ | MEN1 | O00255 | 4/20 | 0.65 |
| ▸ | MAPT | P10636 | 4/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.65 |
| ▸ | ATM | Q13315 | 2/20 | 0.65 |
| ▸ | USP2 | O75604 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | STAT3 | P40763 | 1/20 | 0.56 |
| ▸ | STAT1 | P42224 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15138738 | 0.93 | SLC16A3 (0.78) | SLC16A3ALDH1A1SMN1; SMN2KDM4ESLC16A1 | |
| SCHEMBL16397851 | 0.91 | SLC16A3 (0.72) | SLC16A3ALDH1A1SMN1; SMN2KDM4ESLC16A1 | |
| SCHEMBL42693 | 0.89 | ALDH1A1 (1.00) | SLC16A3ALDH1A1SMN1; SMN2KDM4ESLC16A1 | |
| SCHEMBL29775307 | 0.89 | ALDH1A1 (1.00) | SLC16A3ALDH1A1SMN1; SMN2KDM4ESLC16A1 | |
| SCHEMBL17701081 | 0.89 | SLC16A3 (0.72) | SLC16A3ALDH1A1SMN1; SMN2KDM4ESLC16A1 | |
| SCHEMBL17704691 | 0.88 | MAOB (0.80) | SLC16A3ALDH1A1SMN1; SMN2KDM4ESLC16A1 | |
| SCHEMBL16398053 | 0.88 | SLC16A3 (0.71) | SLC16A3ALDH1A1SMN1; SMN2KDM4ESLC16A1 | |
| SCHEMBL17701069 | 0.87 | SLC16A3 (0.70) | SLC16A3ALDH1A1SMN1; SMN2KDM4ESLC16A1 | |
| SCHEMBL17704699 | 0.86 | SLC16A3 (0.69) | SLC16A3ALDH1A1SMN1; SMN2KDM4ESLC16A1 | |
| SCHEMBL16312149 | 0.86 | MAOB (0.71) | SLC16A3ALDH1A1SMN1; SMN2KDM4ESLC16A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160115146-A1 | 3-CARBOXY SUBSTITUTED COUMARIN DERIVATIVES WITH A POTENTIAL UTILITY FOR THE TREATMENT OF CANCER DISEASES | CISTIM (BE) | 2016-04-28 | — | — | US | disclosed |
| US-20160115146-A1 | 3-CARBOXY SUBSTITUTED COUMARIN DERIVATIVES WITH A POTENTIAL UTILITY FOR THE TREATMENT OF CANCER DISEASES | CISTIM (BE) | 2016-04-28 | — | — | US | disclosed |
| US-20160115146-A1 | 3-CARBOXY SUBSTITUTED COUMARIN DERIVATIVES WITH A POTENTIAL UTILITY FOR THE TREATMENT OF CANCER DISEASES | CISTIM (BE) | 2016-04-28 | — | — | US | disclosed |
| EP-3004073-A1 | 3-CARBOXY SUBSTITUTED COUMARIN DERIVATIVES WITH A POTENTIAL UTILITY FOR THE TREATMENT OF CANCER DISEASES | Université catholique de Louvain (BE) | 2016-04-13 | — | — | EP | disclosed |
| WO-2014195507-A1 | 3-CARBOXY SUBSTITUTED COUMARIN DERIVATIVES WITH A POTENTIAL UTILITY FOR THE TREATMENT OF CANCER DISEASES | UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) | 2014-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160115146-A1 | 3-CARBOXY SUBSTITUTED COUMARIN DERIVATIVES WITH A POTENTIAL UTILITY FOR THE TREATMENT OF CANCER DISEASES | SLC16A3, SLC16A1, SLC16A8 | SLC16A3 1/4885ALDH1A1 160/4885SMN1; SMN2 4024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.